Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)

Next Previous
Trial Profile

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary) ; Corticosteroids
  • Indications Bullous pemphigoid
  • Focus Registrational; Therapeutic Use
  • Acronyms FJORD
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 04 Feb 2024 This trial has been discontinued in Italy ( global end of the trial 2023-07-31),according to European Clinical Trials Database record
  • 04 Feb 2024 This trial has been discontinued in Italy ( global end of the trial 2023-07-31),according to European Clinical Trials Database record
  • 10 Dec 2023 This trial has been discontinued in Bulgaria according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top